Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2010

Open Access 01-12-2010 | Research article

Oxidative stress in skin fibroblasts cultures from patients with Parkinson's disease

Authors: Pilar del Hoyo, Alberto García-Redondo, Fernando de Bustos, José Antonio Molina, Youssef Sayed, Hortensia Alonso-Navarro, Luis Caballero, Joaquín Arenas, José AG Agúndez, Félix Javier Jiménez-Jiménez

Published in: BMC Neurology | Issue 1/2010

Login to get access

Abstract

Background

In the substantia nigra of Parkinson's disease (PD) patients, increased lipid peroxidation, decreased activities of the mitochondrial complex I of the respiratory chain, catalase and glutathione-peroxidase, and decreased levels of reduced glutathione have been reported. These observations suggest that oxidative stress and mitochondrial dysfunction play a role in the neurodegeneration in PD. We assessed enzymatic activities of respiratory chain and other enzymes involved in oxidative processes in skin fibroblasts cultures of patients with PD.

Methods

We studied respiratory chain enzyme activities, activities of total, Cu/Zn- and Mn-superoxide-dismutase, gluthatione-peroxidase and catalase, and coenzyme Q10 levels in skin fibroblasts cultures from 20 Parkinson's disease (PD) patients and 19 age- and sex- matched healthy controls.

Results

When compared with controls, PD patients showed significantly lower specific activities for complex V (both corrected by citrate synthase activity and protein concentrations). Oxidized, reduced and total coenzyme Q10 levels (both corrected by citrate synthase and protein concentrations), and activities of total, Cu/Zn- and Mn-superoxide-dismutase, gluthatione-peroxidase and catalase, did not differ significantly between PD-patients and control groups. Values for enzyme activities in the PD group did not correlate with age at onset, duration, scores of the Unified Parkinson's Disease Rating scales and Hoehn-Yahr staging.

Conclusions

The main result of this study was the decreased activity of complex V in PD patients. This complex synthesizes ATP from ADP using an electrochemical gradient generated by complexes I-IV. These results suggest decreased energetic metabolism in fibroblasts of patients with PD.
Appendix
Available only for authorised users
Literature
1.
Nicklas WJ, Vyas I, Heikkila RE: Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sciences. 1985, 36: 2503-2508. 10.1016/0024-3205(85)90146-8.CrossRefPubMed
2.
Vyas I, Heikkila RE, Nicklas WJ: Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenyl-pyridinium. Journal of Neurochemistry. 1986, 46: 1501-1507. 10.1111/j.1471-4159.1986.tb01768.x.CrossRefPubMed
3.
Mizuno Y, Saitoh T, Sone N: Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity by 1-methyl-4-phenylpyridinium ion. Biochemical and Biophysica. Research Communications. 1987, 143: 294-299. 10.1016/0006-291X(87)90664-4.CrossRef
4.
Alonso-Navarro H, Jiménez-Jiménez FJ, Pilo de la Fuente B, Plaza-Nieto JF: Mecanismos patogénicos de la enfermedad de Parkinson. Tratado de los Trastornos del Movimiento. 2nd edition (ISBN 978-84-85424-76-4). Edited by: Jiménez-Jiménez FJ, Luquin MR, Molina JA, Linazasoro G. 2008, Barcelona: Viguera Editores S.L, 425-485.
5.
Parker WD, Parks JK, Swerdlow RH: Complex I deficiency in Parkinson's disease frontal cortex. Brain Research. 2008, 1189: 215-218. 10.1016/j.brainres.2007.10.061.CrossRefPubMed
6.
Mann V, Cooper JM, Krige D, Daniel SE, Schapira AH, Marsden CD: Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain. 1992, 115: 333-342. 10.1093/brain/115.2.333.CrossRefPubMed
7.
Anderson JJ, Bravi D, Ferrari R, Davis TL, Baronti F, Chase TN, Dagani F: No evidence for altered mitochondrial function in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 1993, 56: 477-480. 10.1136/jnnp.56.5.477.CrossRefPubMedPubMedCentral
8.
Di Donato S, Zeviani M, Giovannini P, Savarese N, Rimoldi M, Mariotti C, Girotti F, Caraceni T: Respiratory chain and mitochondrial DNA in muscle and brain in Parkinson's disease patients. Neurology. 1993, 43: 2262-2268.CrossRef
9.
Di Monte DA, Sandy MS, Jewell SA, Langston JW: Oxidative phosphorylation by intact muscle mitochondrial function in Parkinson's disease. Neurodegeneration. 1993, 2: 275-281.
10.
Reichmann H, Janetzky B, Bischop F, Seibel P, Schöls L, Kuhn W, Przuntek H: Unaltered respiratory chain enzyme activity and mitochondrial DNA in skeletal muscle of patients with idiopathic Parkinson's syndrome. European Neurology. 1994, 34: 263-267. 10.1159/000117053.CrossRefPubMed
11.
Bindoff LA, Birch-Machin M, Cartlidge NE, Parker WD, Turnbull DM: Mitochondrial function in Parkinson's disease. The Lancet. 1989, 2: 49-10.1016/S0140-6736(89)90291-2.CrossRef
12.
Bindoff LA, Birch-Machin M, Cartlidge NE, Parker WD, Turnbull DM: Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease. Journal of the Neurological Sciences. 1991, 104: 203-208. 10.1016/0022-510X(91)90311-T.CrossRefPubMed
13.
Nakagawa-Hattori Y, Yoshino H, Kondo T, Mizuno Y, Horai S: Is Parkinson's disease a mitochondrial disease?. Journal of the Neurological Sciences. 1992, 107: 29-33. 10.1016/0022-510X(92)90205-Y.CrossRefPubMed
14.
Shoffner JM, Watts RL, Juncos JL, Torroni A, Wallace DC: Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Annals of Neurology. 1992, 32: 226-227. 10.1002/ana.410320221.CrossRef
15.
Cardellach F, Martí MJ, Fernández-Sola J, Marín C, Hoek B, Tolosa E, Urbano-Márquez A: Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. Neurology. 1993, 43: 2258-2262.CrossRefPubMed
16.
Blin O, Desnuelle C, Rascol O, Borg M, Peyro-Saint Paul H, Azulay JP, Bille F, Figarella D, Coulom F, Pellissier JF, et al: Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy. Journal of the Neurological Sciences. 1994, 125: 95-101. 10.1016/0022-510X(94)90248-8.CrossRefPubMed
17.
Winkler-Stuck K, Kirches E, Mawrin C, Dietzmann K, Lins H, Wallesch CW, Kunz WS, Wiedemann FR: Re-evaluation of the dysfunction of mitochondrial respiratory chain in skeletal muscle of patients with Parkinson's disease. Journal of Neural Transmission. 2005, 112: 499-518. 10.1007/s00702-004-0195-y.CrossRefPubMed
18.
Bravi D, Anderson JJ, Dagani F, Davis TL, Ferrari R, Gillespie M, Chase TN: Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease. Movement Disorders. 1992, 7: 228-231. 10.1002/mds.870070307.CrossRefPubMed
19.
Blake CI, Spitz E, Leehey M, Hoffer BJ, Boyson SJ: Platelet mitochondrial respiratory chain function in Parkinson's disease. Movement Disorders. 1997, 12: 3-8. 10.1002/mds.870120103.CrossRefPubMed
20.
Hanagasi HA, Ayribas D, Baysal K, Emre M: Mitochondrial complex I, II/III, and IV activities in familial and sporadic Parkinson's disease. International Journal of Neurosciences. 2005, 115: 479-493. 10.1080/00207450590523017.CrossRef
21.
Parker WD, Boyson SJ, Parks JK: Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Annals of Neurology. 1989, 26: 719-723. 10.1002/ana.410260606.CrossRefPubMed
22.
Krige D, Carrol MT, Cooper JM, Marsden CD, Schapira AH: Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Annals of Neurology. 1992, 32: 782-788. 10.1002/ana.410320612.CrossRefPubMed
23.
Yoshino H, Nakagawa-Hattori Y, Kondo T, Mizuno Y: Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. Journal of Neural Transmission (Parkinson's Disease Section). 1992, 4: 27-34. 10.1007/BF02257619.CrossRef
24.
Benecke R, Strumper P, Weiss H: Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain. 1992, 116: 1451-1463. 10.1093/brain/116.6.1451.CrossRef
25.
Haas RH, Nasirian F, Nakano K, Ward D, Pay M, Hill R, Shults CW: Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Annals of Neurology. 1995, 37: 714-722. 10.1002/ana.410370604.CrossRefPubMed
26.
Varghese M, Pandey M, Samanta A, Gangopadhyay PK, Mohanakumar KP: Reduced NADH coenzyme Q dehydrogenase activity in platelets of Parkinson's disease, but not Parkinson plus patients, from an Indian population. Journal of the Neurological Sciences. 2009, 279: 39-42. 10.1016/j.jns.2008.12.021.CrossRefPubMed
27.
Barroso N, Campos Y, Huertas R, Esteban J, Molina JA, Alonso A, Gutiérrez-Rivas E, Arenas J: Respiratory chain enzyme activities in lymphocytes from untreated patients with Parkinson disease. Clinical Chemistry. 1993, 39: 667-669.PubMed
28.
Martín MA, Molina JA, Jiménez-Jiménez FJ, Benito-León J, Ortí-Pareja M, Campos Y, Arenas J, Grupo Centro de Trastornos del Movimiento: Respiratory chain enzyme activities in isolated mitochondria of lymphocytes from untreated Parkinson's disease patients. Neurology. 1996, 46: 1343-1346.CrossRefPubMed
29.
Shinde S, Pasupathy K: Respiratory-chain enzyme activities in isolated mitochondria of lymphocytes from patients with Parkinson's disease: preliminary study. Neurology India. 2006, 54: 390-393. 10.4103/0028-3886.28112.CrossRefPubMed
30.
Muftuoglu M, Elibol B, Dalmizrak O, Ercan A, Kulaksiz G, Ogus H, Dalkara T, Ozer N: Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Movement Disorders. 2004, 19: 544-548. 10.1002/mds.10695.CrossRefPubMed
31.
Molina JA, Ruiz-Pesini E, Jiménez-Jiménez FJ, López-Pérez MJ, Alvarez E, Berbel A, Ortí-Pareja M, Zurdo M, Tallón-Barranco A, de Bustos F, Arenas J: Respiratory chain enzyme activity in spermatozoa from untreated Parkinson's disease patients. Journal of Neural Transmission. 1999, 106: 919-924. 10.1007/s007020050211.CrossRefPubMed
32.
Wiedemann FR, Winkler K, Lins H, Wallesch CW, Kunz WS: Detection of respiratory chain defects in cultivated skin fibroblasts and skeletal muscle of patients with Parkinson's disease. Annals of the New York Academy of Sciences. 1999, 893: 426-429. 10.1111/j.1749-6632.1999.tb07870.x.CrossRefPubMed
33.
Winkler-Stuck K, Wiedemann FR, Wallesch CW, Kunz WS: Effect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patients. Journal of the Neurological Sciences. 2004, 220: 41-48. 10.1016/j.jns.2004.02.003.CrossRefPubMed
34.
Piccoli C, Sardanelli A, Scrima R, Ripoli M, Quarato G, D'Aprile A, Bellomo F, Scacco S, De Michele G, Filla A, Iuso A, Boffoli D, Capitanio N, Papa S: Mitochondrial respiratory dysfunction in familiar parkinsonism associated with PINK1 mutation. Neurochemical Research. 2008, 33: 2565-2574. 10.1007/s11064-008-9729-2.CrossRefPubMed
35.
Ferrer I, Pérez E, Dalfó E, Barrachina M: Abnormal levels of prohibitin and ATP synthase in the substantia nigra and frontal cortex in Parkinson's disease. Neuroscience Letters. 2007, 415: 205-209. 10.1016/j.neulet.2007.01.026.CrossRefPubMed
36.
Schapira AHV: Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurology. 2008, 7: 97-109. 10.1016/S1474-4422(07)70327-7.CrossRefPubMed
37.
Ambani LM, Van Woert MH, Murphy S: Brain peroxidase and catalase in Parkinson disease. Archives of Neurology. 1975, 32: 114-118.CrossRefPubMed
38.
Kish SJ, Morito C, Hornykiewicz O: Glutathione peroxidase activity in Parkinson's disease. Neuroscience Letters. 1985, 58: 343-346. 10.1016/0304-3940(85)90078-3.CrossRefPubMed
39.
Marttila RJ, Lorentz H, Rinne UK: Oxygen toxicity protecting enzymes in Parkinson's disease: increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. Journal of the Neurological Sciences. 1988, 86: 321-331. 10.1016/0022-510X(88)90108-6.CrossRefPubMed
40.
Saggu H, Cooksey J, Dexter D, Wells FR, Lees A, Jenner P, Marsden CD: A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. Journal of Neurochemistry. 1989, 53: 692-697. 10.1111/j.1471-4159.1989.tb11759.x.CrossRefPubMed
41.
Choi J, Rees HD, Weintraub ST, Levey AI, Chin LS, Li L: Oxidative modifications and aggregation of Cu,Zn-superoxide dismutase associated with Alzheimer and Parkinson disease. Journal of Biological Chemistry. 2005, 280: 11648-11655. 10.1074/jbc.M414327200.CrossRefPubMed
42.
Radunovic A, Porto WG, Zeman S, Leigh PN: Increased mitochondrial superoxide dismutase activity in Parkinson's disease but not amyotrophic lateral sclerosis motor cortex. Neuroscience Letters. 1997, 239: 105-108. 10.1016/S0304-3940(97)00905-1.CrossRefPubMed
43.
Ernster L, Dallner G: Biochemical, physiological and medical aspects of ubiquinone function. Annals of Neurology. 1995, 42: 261-264.
44.
Shults CQ, Haas RH, Passov D, Beal MF: Coenzyme Q10 levels correlate with the activities of complexes I and II/III mitochondria from parkinsonian and nonparkinsonian patients. Annals of Neurology. 1997, 42: 261-264. 10.1002/ana.410420221.CrossRefPubMed
45.
Gotz ME, Gerstner A, Harth R, Dirr A, Janetzky B, Kuhn W, Riederer P, Gerlach M: Altered redox state of platelet coenzyme Q10 in Parkinson's disease. Journal of Neural Transmission. 2000, 107: 41-48. 10.1007/s007020050003.CrossRefPubMed
46.
Zheng X, Shoffner JM, Voljavec AS, Wallace DC: Evaluation of procedures for assaying oxidative phosphorylation enzyme activies in mitochondrial myopathy muscle biopsies. Biochimica Biophysica Acta. 1990, 101: 1-10.CrossRef
47.
Lowry OH, Rosebrough NJ, Farr AL, Randall RS: Protein measurement with the Folin phenlo reagent. Journal of Biological Chemistry. 1951, 193: 265-271.PubMed
48.
Flohé L, Günzler W: Assays of glutathione peroxidase. Methods in Enzymology. 1984, 105: 114-121. full_text.CrossRefPubMed
49.
50.
Spitz DR, Oberley LW: An assay for superoxide dismutase activity in mammalian tissue homogenates. Analitical Biochemistry. 1989, 179: 8-18. 10.1016/0003-2697(89)90192-9.CrossRef
51.
Langedijk J, Ubbink JB, Vermaak WJH: Measurement of the ratio between the reduced and oxidized forms of coenzyme Q10 in human plasma as a possible marker of oxidative stress. Journal of Lipid Research. 1996, 37: 67-75.
Metadata
Title
Oxidative stress in skin fibroblasts cultures from patients with Parkinson's disease
Authors
Pilar del Hoyo
Alberto García-Redondo
Fernando de Bustos
José Antonio Molina
Youssef Sayed
Hortensia Alonso-Navarro
Luis Caballero
Joaquín Arenas
José AG Agúndez
Félix Javier Jiménez-Jiménez
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2010
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/1471-2377-10-95

Other articles of this Issue 1/2010

BMC Neurology 1/2010 Go to the issue

Study protocol

Promotion of the mind through exercise (PROMoTE): a proof-of-concept randomized controlled trial of aerobic exercise training in older adults with vascular cognitive impairment

Research article

Clinical profile of parkinsonism and Parkinson's disease in Lagos, Southwestern Nigeria

Research article

Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study

Research article

Treatment of cyclic vomiting syndrome with co-enzyme Q10 and amitriptyline, a retrospective study

Research article

Hypogelsolinemia, a disorder of the extracellular actin scavenger system, in patients with multiple sclerosis

Research article

Diagnosing migraine in research and clinical settings: The validation of the Structured Migraine Interview (SMI)